IsoRay, a provider of brachytherapy seeds for the treatment of prostate cancer and other solid tumors, announced that the first brachytherapy implants for cancer treatment of the eye were performed using its cesium-131 seeds at Tufts-New England Medical Center on Wednesday.
The Boston-based IsoRay said its cesium-131, a medical isotope marketed under the brand Proxcelan, has been used in over 1,900 prostate cancer brachytherapy procedures since October 2004.
Isoray said three patients received implants for intraocular melanoma, performed with the support of Mark J. Rivard, PhD, associate professor of radiation oncology at Tufts University School of Medicine and chief medical physicist at Tufts-New England Medical Center.
During the procedures, cesium-131 brachytherapy seeds, encased in a small disc-shaped shield (plaque) with a protective gold backing, were attached to the surface of the patients’ eyes over the area to be treated, according to IsoRay. The plaques are scheduled to be removed on Dec. 17.